WCLC 2026 Highlights: MAVERICK, ADAURA, HARMONi, PAPILLON, DESTINY-Lung04 with Dr. Christine Lovly

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Christine Lovly, a thoracic medical oncologist from City of Hope, to discuss key studies presented at the World Conference on Lung Cancer 2026.

We dived into five pivotal studies, including:

• MAVERICK: study on the role of MRI surveillance in small cell lung cancer (SCLC), showing that prophylactic cranial irradiation (PCI) may no longer be necessary
• ADAURA Update: 8-year update continues to show benefit of adjuvant osimertinib for early-stage EGFR-mutant lung cancer, with an impressive overall survival (OS) benefit
• HARMONi: potential of ivonescimab, a PD-1 and VEGF bispecific antibody, in the treatment of EGFR-positive disease after progression on third-generation therapies
• PAPILLON: discussion on the frontline treatment options for EGFR exon 20 insertion mutations, including the role of amivantamab and the anticipated approval of sunvozertinib
• DESTINY-Lung04: an analysis of trastuzumab deruxtecan (T-DXd) in HER2-mutated lung cancer and its implications for treatment strategies

Join us as we explore the latest advancements in lung cancer treatment and the importance of biomarker testing. Don't miss this informative episode packed with insights for oncologists and healthcare professionals!

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

• X/Twitter: https://x.com/oncbrothers
• ⁠Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Subscribe for more updates and discussions on the latest in oncology research and practice!

#LungCancer, #WCLC2026, #Osimertinib, #Ivonescimab, #MAVERICK, #PAPILLON, #TDXd, #OncologyBrothers